Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-0039.1992.tb02153.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Autoimmune Thyroid disease and Oral Lichen Planus: A Multi-Omic Genetic Analysis.
Int Dent J
December 2024
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, China. Electronic address:
Article Synopsis
- The study examines the genetic connection between autoimmune thyroid disease (AITD) and oral lichen planus (OLP), which may reveal how these conditions are related.
- A two-step Mendelian randomization analysis identified that AITD may increase the risk of developing OLP, possibly influenced by hypothyroidism and shared genetic factors, particularly the PTPN22 gene.
- The research emphasizes the importance of understanding endocrine changes in oral health, suggesting a need for further investigation to confirm these findings.
Mediation effect of plasma metabolites on the relationship between immune cells and the risk of prostatitis: A study by bidirectional 2-sample and Bayesian-weighted Mendelian randomization.
Medicine (Baltimore)
October 2024
Department of Urology, Wuhu Hospital of Traditional Chinese Medicine, Wuhu, Anhui Province, China.
According to the findings of multiple observational studies, immune disorder was a risk factor for prostatitis. However, it remained unknown whether there was a direct causal relationship between immune cells and prostatitis or whether this relationship was mediated by plasma metabolites. Based on the pooled data of a genome-wide association study (GWAS), a genetic variant was used to predict the effects of 731 immunophenotypes on the risk of prostatitis and determine whether the effects were mediated by 1400 metabolites.
View Article and Find Full Text PDFMolecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization.
Front Immunol
July 2024
Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Naples, Italy.
Article Synopsis
- The study explored the relationship between SARS-CoV-2 peptides and tumor-associated antigens (TAAs) to find if they could trigger similar immune responses.
- Researchers identified that many SARS-CoV-2 proteins, particularly the Spike protein from the BNT162b2 vaccine, share significant amino acid sequences with TAAs linked to various cancers like breast and melanoma.
- Findings suggest that prior infection or vaccination against COVID-19 could potentially offer immunity against certain cancers, opening avenues for developing new "multi-cancer" vaccines that exploit these viral similarities for therapeutic benefits.
Construction and efficacy testing of DNA vaccines containing HLA-A*02:01-restricted SARS-CoV-2 T-cell epitopes predicted by immunoinformatics.
Acta Biochim Biophys Sin (Shanghai)
April 2024
Key Laboratory of Medical Molecular Virology (NHC & MOE & CAMS), Shanghai Institute of Infectious Diseases and Biosecurity, Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200031, China.
Vaccines play essential roles in the fight against the COVID-19 pandemic. The development and assessment of COVID-19 vaccines have generally focused on the induction and boosting of neutralizing antibodies targeting the SARS-CoV-2 spike (S) protein. Due to rapid and continuous variation in the S protein, such vaccines need to be regularly updated to match newly emerged dominant variants.
View Article and Find Full Text PDFEnhanced T cell receptor specificity through framework engineering.
Front Immunol
March 2024
Department of Chemistry and Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, United States.
Development of T cell receptors (TCRs) as immunotherapeutics is hindered by inherent TCR cross-reactivity. Engineering more specific TCRs has proven challenging, as unlike antibodies, improving TCR affinity does not usually improve specificity. Although various protein design approaches have been explored to surmount this, mutations in TCR binding interfaces risk broadening specificity or introducing new reactivities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!